March 22, 2019
A Friday, mid-month of March’s 15 sessions, having 5 negative and 10 positive closes
Is the market casino, after a week of split decisions; the dice are cold?
Pre-open indication: 1 BUY, 4 SELL and 3 TRADEs
My focuses is indication analysis. An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation. The sole provision is that it provides insight!
March 19, 2019
SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket
Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.
March 22, 2019
… 40 of 45 covered companies didn’t pay-off with the IBB closing down -3.39%
Volume was low as 1 out of the 2 upside had higher (than the 3 month average) volume and 17 out of the 40 downside experienced greater volume (than the 3 month average)
… Algorithms, algorithms compute me your “rules”
Q4 and FY18 financial results: Neuralstem (CUR)
Pre-open indications: 7 HIT and 1 MISS
Review the snapshot of the daily ‘workings” of the sector composite of cell and gene therapy companies.
March 19, 2019
SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.
March 16, 2019
Q4/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 32 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"
March 12, 2019
OSIR is up +$0.14 or +0.74% to $19.02 having closed at $18.88 This offer represents a 37% premium to its 90-day volume-weighted average stock price
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
March 22, 2019
RegMed Investors’ (RMi) closing bell: Investors were cleaned-out by today’s action
March 22, 2019
RegMed Investors’ (RMi) pre-open: gain or pain
March 21, 2019
RegMed Investors’ (RMi) closing bell: the oversold were ‘rushed” to the upside and succeeded
March 21, 2019
RegMed Investors’ (RMi) pre-open: indications are negative as indexes and ETFs look even more dismal
March 20, 2019
RegMed Investors’ (RMi) pre-open: there is nothing like an FDA approval to ignite the sector
March 19, 2019
Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression (severe depression after childbirth) therapy
March 19, 2019
RegMed Investors’ (RMi) closing bell: the sector decelerates as the IBB (-0.06%) drifts
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
